RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 33, 2013, Pages 13522-13527

  Girard, Nathalie ^a,b,c   Tremblay, Mathieu ^a,c   Humbert, Magali ^a   Grondin, Benoît ^a   Haman, André ^a   Labrecque, Jean ^a,b   Chen, Bing ^d,e   Chen, Zhu ^d,e   Chen, Sai Juan ^d,e   Hoang, Trang ^a,b,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c Molecular Biology Program   (Canada)

^d State Key Laboratory of Medical Genomics   (China)

^e SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

APL; Granulocyte differentiation; Histone modification; Protein interaction; Transcription inhibition

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE 1; HISTONE H3; INTERLEUKIN 3; MICRORNA 223; RETINOIC ACID RECEPTOR ALPHA; STAT PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER RETINOIC ACID RECEPTOR ALPHA;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL SURVIVAL; CLONAL VARIATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; DEACETYLATION; DNA BINDING; FETUS; GENE EXPRESSION; GENE LOCUS; GENETIC TRANSDUCTION; HUMAN; IN VITRO STUDY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; ZINC FINGER RETINOIC ACID RECEPTOR ALPHA ONCOGENE;

APL; GRANULOCYTE DIFFERENTIATION; HISTONE MODIFICATION; PROTEIN INTERACTION; TRANSCRIPTION INHIBITION;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE TRANSFER TECHNIQUES; GRANULOCYTE PRECURSOR CELLS; GRANULOCYTES; HISTONE DEACETYLASE 1; HISTONES; HUMANS; IMMUNOPRECIPITATION; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKEMIA, PROMYELOCYTIC, ACUTE; ONCOGENE PROTEINS, FUSION; RECEPTORS, RETINOIC ACID; TRANSLOCATION, GENETIC;

EID: 84882373704     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1310067110     Document Type: Article

References (38)

1. de Thé H, Chen Z (2010) Acute promyelocytic leukaemia: Novel insights into the mechanisms of cure. Nat Rev Cancer 10(11):775-783.
2. Melnick A, Licht JD (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93(10):3167-3215.
3. Scaglioni PP, Pandolfi PP (2007) The theory of APL revisited. Curr Top Microbiol Immunol 313:85-100.
4. Kastner P, et al. (2001) Positive and negative regulation of granulopoiesis by endogenous RARalpha. Blood 97(5):1314-1320.
5. Labrecque J, et al. (1998) Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors alpha1 and gamma. Blood 92(2):607-615.
6. Du C, Redner RL, Cooke MP, Lavau C (1999) Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood 94(2):793-802.
7. Licht JD, et al. (1995) Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85(4):1083-1094.
8. Chen Z, et al. (1993) Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 12(3):1161-1167.
9. Jovanovic JV, et al. (2011) Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia. Front Oncol 1:35.
10. Boukarabila H, et al. (2009) The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev 23(10):1195-1206.
11. Cheng GX, et al. (1999) Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci USA 96(11):6318-6323.
12. He LZ, et al. (2000) Two critical hits for promyelocytic leukemia. Mol Cell 6(5):1131-1141.
13. Ivins S, et al. (2003) Regulation of Hoxb2 by APL-associated PLZF protein. Oncogene 22(24):3685-3697.
14. McConnell MJ, et al. (2003) Growth suppression by acute promyelocytic leukemiaassociated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol 23(24):9375-9388.
15. Yeyati PL, et al. (1999) Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 18(4):925-934.
16. Guidez F, et al. (2007) RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc Natl Acad Sci USA 104(47):18,694-18,699.
17. Pabst T, et al. (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27(3):263-270.
18. Löwenberg B (2008) Diagnosis and prognosis in acute myeloid leukemia-the art of distinction. N Engl J Med 358(18):1960-1962.
19. Paz-Priel I, Friedman A (2011) C/EBP? dysregulation in AML and ALL. Crit Rev Oncog 16(1-2):93-102.
20. Zhang P, et al. (2004) Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity 21(6):853-863.
21. Rajotte D, et al. (1996) Contribution of both STAT and SRF/TCF to c-fos promoter activation by granulocyte-macrophage colony-stimulating factor. Blood 88(8):2906-2916.
22. Smith LT, Hohaus S, Gonzalez DA, Dziennis SE, Tenen DG (1996) PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood 88(4):1234-1247.
23. Wang QF, Friedman AD (2002) CCAAT/enhancer-binding proteins are required for granulopoiesis independent of their induction of the granulocyte colony-stimulating factor receptor. Blood 99(8):2776-2785.
24. Fazi F, et al. (2005) A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 123(5):819-831.
25. Ford AM, et al. (1996) Regulation of the myeloperoxidase enhancer binding proteins Pu1, C-EBP alpha,-beta, and-delta during granulocyte-lineage specification. Proc Natl Acad Sci USA 93(20):10,838-10,843.
26. Khanna-Gupta A, Zibello T, Sun H, Gaines P, Berliner N (2003) Chromatin immunoprecipitation (ChIP) studies indicate a role for CCAAT enhancer binding proteins alpha and epsilon (C/EBP alpha and C/EBP epsilon ) and CDP/cut in myeloid maturationinduced lactoferrin gene expression. Blood 101(9):3460-3468.
27. Oelgeschläger M, Nuchprayoon I, Lüscher B, Friedman AD (1996) C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol Cell Biol 16(9):4717-4725.
28. Li JY, et al. (1997) Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. J Biol Chem 272(36):22,447-22,455.
29. Grondin B, et al. (2007) c-Jun homodimers can function as a context-specific coactivator. Mol Cell Biol 27(8):2919-2933.
30. Guidez F, et al. (1998) Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91(8):2634-2642.
31. Melnick A, et al. (2002) Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol 22(6):1804-1818.
32. Doulatov S, et al. (2009) PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes Dev 23(17):2076-2087.
33. He LZ, et al. (1998) Distinct interactions of PML-RARalpha and PLZF-RARalpha with corepressors determine differential responses to RA in APL. Nat Genet 18(2):126-135.
34. Spicuglia S, et al. (2011) Characterisation of genome-wide PLZF/RARA target genes. PLoS ONE 6(9):e24176.
35. Vickers M, Jackson G, Taylor P (2000) The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia 14(4):722-726.
36. Hoang T, et al. (1996) Opposing effects of the basic helix-loop-helix transcription factor SCL on erythroid and monocytic differentiation. Blood 87(1):102-111.
37. Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T (2000) SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol 1(2):138-144.
38. Lécuyer E, et al. (2002) The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1. Blood 100(7):2430-2440.